KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) EBT Margin (2016 - 2025)

Arbutus Biopharma's EBT Margin history spans 13 years, with the latest figure at 1461.25% for Q3 2025.

  • For Q3 2025, EBT Margin rose 1164.0% year-over-year to 1461.25%; the TTM value through Sep 2025 reached 289.31%, up 84809.0%, while the annual FY2024 figure was 1133.04%, 73147.0% down from the prior year.
  • EBT Margin for Q3 2025 was 1461.25% at Arbutus Biopharma, down from 23.3% in the prior quarter.
  • Across five years, EBT Margin topped out at 23.3% in Q2 2025 and bottomed at 1472.89% in Q3 2024.
  • The 5-year median for EBT Margin is 665.03% (2021), against an average of 686.0%.
  • The largest annual shift saw EBT Margin plummeted -104129bps in 2024 before it skyrocketed 116976bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 665.03% in 2021, then surged by 47bps to 351.19% in 2022, then tumbled by -156bps to 900.33% in 2023, then rose by 12bps to 794.09% in 2024, then crashed by -84bps to 1461.25% in 2025.
  • Per Business Quant, the three most recent readings for ABUS's EBT Margin are 1461.25% (Q3 2025), 23.3% (Q2 2025), and 1390.59% (Q1 2025).